1. **Executive Session** 6:00 - 6:30
   - Discussion on Medicaid OBRA’90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes** 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates** 6:35 - 6:45
   - Updates

4. **Medical Director Update** 6:45 - 6:50
   - Clinical Programs Update
   - Prescriber Comments

5. **Follow-up Items from Previous Meetings** 6:50 - 7:05
   - Buprenorphine and Opiates
   - Long Acting Injectable Antipsychotic Medications
   - Pulmonary: Short Acting Beta-Agonist Inhalers

6. **RetroDUR/DUR** 7:05 – 7:25
   - Buprenorphine and Benzodiazepines

7. **Clinical Update: Drug Reviews** 7:25 – 7:55
   (Public comment prior to Board action)

**Abbreviated New Drug Reviews**
- Cystaran® (cysteamine) Ophthalmic Solution
- Diclegis® (doxylamine succinate/pyridoxine) DR Oral Tablet
- Namenda® XR (memantine) Oral Capsule
- Prolensa® (bromfenac 0.07 %) Ophthalmic Solution
- Simbrinza® (brinzolamide 1 %/ brimonidine 0.2 %) Ophthalmic Suspension

**Full New Drug Reviews**
- Invokana® (canagliflozin) Oral Tablet
8. Therapeutic Drug Classes – Periodic Review 7:55 – 8:20
(Public comment prior to Board action)
Class review documents available on DVHA web site 10/22/2013 @ Noon
- Acne Medications: Topical
- Anti-hypertensives: Angiotensin Converting Enzyme (ACE) Inhibitors and Combinations
- Anti-hypertensives: Angiotensin Receptor Blockers and Combinations
- Gastrointestinal: H2 Receptor Antagonists
- Otic: Anti-Infectives
- Renal: Phosphate Binders
- Vitamins: Prenatal

9. New Managed Therapeutic Drug Classes 8:20– 8:20
(Public comment prior to Board action)
- None

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:20 – 8:25
(Public comment prior to Board action)
- Anti-diabetics: DPP4 Inhibitors (1/1/2014)
- Anti-infectives: Antivirals: Influenza Vaccines
- Anti-infectives: Cephalosporins: 3rd Generation (1/1/2014)
- Gastrointestinal: Proton Pump Inhibitors (1/1/2014)
- Pulmonary: Corticosteroids: Intranasal (1/1/2014)

11. General Announcements 8:25– 8:30
Selected FDA Safety Alerts
- Acetaminophen: Drug Safety Communication - Association with Risk of Serious Skin Reactions
- Gilenya: Drug Safety Communication - Possible PML Case in Europe
- Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
- Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection

12. Adjourn 8:30